2026 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
Insights
Categories
Topics
Categories
Topics
2026 Artemetrx State of Specialty Spend and Trend Report Webinar
July 23 | 12:00pm CT PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug…
Read Post
2026 Trends in Drug Benefit Design Report
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
2026 GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes
Join us for an in-depth exploration of one of the most impactful developments in prescription drug benefits: GLP-1 medications for type 2 diabetes and…
Read Post
PSG Report Finds Payers Reassessing GLP-1 Coverage, PBM Models, and Cost-Sharing Strategies
New research highlights affordability concerns, more interest in alternative approaches, and uncertainty around direct-to-consumer offerings DALLAS – June 9, 2026 – Pharmaceutical Strategies Group (“PSG”), an EPIC…
Read Post
Manage Pharmacy Spend and Trend: Artemetrx Analytics Overview
PSG’s Proprietary Data and Analytics Tool, Artemetrx Pharmacy benefit costs are shaped by a complex mix of spend drivers, utilization patterns, clinical decisions, and…
Read Post
PSG’s Perspective on AI in Healthcare and Pharmacy Benefits
Leveraging AI to Better Identify Fraud, Waste, and Abuse (FWA) Key Points Responsible AI implementation brings clarity to pharmacy benefit strategy when it is…
Read Post
Making Sense of GLP-1 Carve-Out Strategies
How Payers Can Adapt to the Rapidly Changing GLP-1 Landscape Key Points GLP-1 medications are driving rapid utilization growth that traditional pharmacy benefit designs are…
Read Post
Proactive PBM Oversight Protects Cost Savings During a Humira Biosimilar Transition
During a PBM transition, errors within a Humira biosimilar strategy cost three large employers a combined ~$750,000 in savings, which PSG quickly identified through…
Read Post
Guide For Health Plans: Formulary Benchmarking
PSG Provides Insight To Support Your Formulary Strategy Health plans face increasing pressure to optimize formulary design in ways that balance clinical appropriateness, member…
Read Post
Flexible Procurement Design Supports Complex Benefit Structures
Two large employers were navigating the challenges of comparing traditional procurement options to a carved-out approach. PSG was able to help standardize the process…
Read Post
2026 Trends in Drug Benefit Design Report Webinar
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post